By Gary K. Schwartz

Professional physician-scientists and clinicians assessment these combos of novel objective brokers vintage chemotherapies that carry the main promise for the way forward for clinical oncology, and aspect their optimum series, pharmacokinetic interactions, and interplay with downstream mobile signs. The combos run the gamut of particular cures opposed to mobile floor receptors (EGF-R and HER2), the mobilephone cycle (the CDKs), sign transduction occasions (PKC and NF-kB), apoptosis (bcl-2), in addition to targeted cures in ovarian melanoma, hematologic illnesses, and breast melanoma. The authors emphasize novel translational ways which are quickly relocating from the laboratory bench best to the patient's bedside for the longer term remedies in melanoma remedy.

Show description

Read or Download Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development) PDF

Best oncology books

Evaluating Alternative Cancer Therapies: A Guide to the Science and Politics of an Emerging Medical Field

In comparing substitute melanoma cures, David Hess has interviewed the foremost opinion leaders within the substitute melanoma treatment box - clinicians, researchers, sufferer advocacy leaders, and reporters - who clarify their philosophy of overview, their healing personal tastes, and the political and financial hurdles to getting the mandatory learn performed.

Malignant Melanoma - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

It is a 3-in-1 reference publication. It offers an entire clinical dictionary overlaying enormous quantities of phrases and expressions with regards to malignant cancer. It additionally provides large lists of bibliographic citations. ultimately, it presents details to clients on easy methods to replace their wisdom utilizing quite a few net assets.

Palliative Care in Oncology

Palliative care presents finished aid for seriously affected sufferers with any life-limiting or life-threatening prognosis. to do that successfully, it calls for a disease-specific technique because the sufferers’ wishes and scientific context will range reckoning on the underlying prognosis. specialists within the box of palliative care and oncology describe intimately the desires of sufferers with complex melanoma compared to people with non-cancer ailment and likewise establish the necessities of sufferers with diversified melanoma entities.

100 questions and answers about bipolar (manic-depressive) disorder

Offers doctor's and patient's perspectives of bipolar ailment. summary: the one quantity to supply the doctor's and patient's view and provides you authoritative, sensible solutions for your questions on treatment plans, coping ideas. learn extra. ..

Additional resources for Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)

Example text

FEBS Lett 1997;410:83–86. 9. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49–139. 10. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999;68:965–1014. 11. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355–365. 12. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer.

001) (71,148). Therefore, when either flavopiridol or bryostatin-1 is given first, as a consequence of cell-cycle-mediated drug resistance, paclitaxel sensitivity is markedly reduced. In the case of flavopiridol, cells are arrested in the cell cycle and are insensitive to paclitaxel, which asserts its activity as cells enter M phase. In the case of bryostatin-1, cyclin B1–cdc2 kinase activity is reduced, resulting in cells arresting in G2, as the cyclin B1–cdc2 kinase is associated with the activity of the spindle-assembly checkpoint (139), and is required to initiate entry into M phase (2).

In the case of flavopiridol, cells are arrested in the cell cycle and are insensitive to paclitaxel, which asserts its activity as cells enter M phase. In the case of bryostatin-1, cyclin B1–cdc2 kinase activity is reduced, resulting in cells arresting in G2, as the cyclin B1–cdc2 kinase is associated with the activity of the spindle-assembly checkpoint (139), and is required to initiate entry into M phase (2). Koutcher et al. demonstrated the G2 cell-cycle arrest in vitro: treatment of human MKN-74 gastric cancer cells with bryostatin-1 followed by paclitaxel resulted in a decrease in cells entering M phase (23% vs 56% with paclitaxel alone), and a concomitant increase in cells in G2 (69% vs 21% with paclitaxel alone) (71).

Download PDF sample

Rated 4.01 of 5 – based on 12 votes